At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Busulfan +1 moredrug
Likely dose
Busulfan 130 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study
In Brief
A Phase 2 clinical trial evaluating Busulfan and Fludarabine for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This is a phase II study of allogeneic hematopoietic progenitor cell transplantation (HPCT) followed reduced toxicity conditioning with once daily intravenous Busulfex and fludarabine in patients with relapsed/chemotherapy refractory Hodgkin's and non-Hodgkin's lymphomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin's Lymphoma, Non-Hodgkin's Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartOct 2010
Primary CompletionSep 2021
TodayJul 2026
First PostedSep 16, 2010
Enrollment StartOct 12, 2010
Primary CompletionSep 27, 2021
TodayJul 2, 2026
Enrollment to primary: 11.0 yearsPosted 15.8 years ago
Interventions
Busulfandrug
Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
Fludarabinedrug
Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)